- Home
- ERAS
ERAS
Erasca Inc.
as 07-26-2024 4:00pm EST
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 892.1M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.51 - $3.45 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Erasca Inc. (ERAS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Casdin Alexander W. | ERAS | Director | May 21 '24 | Buy | $2.27 | 80,000 | $181,920.00 | 573,974 | SEC Form 4 |
| Lim Jonathan E | ERAS | Chairman & CEO | Dec 5 '23 | Buy | $1.69 | 721,850 | $1,217,760.95 | 12,899,360 | SEC Form 4 |
| Lim Jonathan E | ERAS | Chairman & CEO | Dec 5 '23 | Buy | $1.72 | 278,150 | $478,418.00 | 12,899,360 | SEC Form 4 |
| Casdin Alexander W. | ERAS | Director | Dec 4 '23 | Buy | $1.66 | 30,000 | $49,785.00 | 493,974 | SEC Form 4 |
Latest Erasca Inc. News
ERAS Breaking Stock News: Dive into ERAS Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a month ago
Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma
GlobeNewswire
a month ago
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
GlobeNewswire
2 months ago
Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
PR Newswire
2 months ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
Business Wire
2 months ago
Form 8.3 - International Distribution Services plc
Business Wire
2 months ago
Form 8.3 - Darktrace plc
Reuters
2 months ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Investor's Business Daily
2 months ago
Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect
Compare ERAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERAS Erasca Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.